8 results about "Sialidase activity" patented technology

The invention provides compositions and methods for treating a patient with cancer with an immune cell, e.g., a T-cell, e.g., an engineered T-cell, with increased sialidase activity. The invention also provides compositions and methods for treating a patient with cancer with an immune cell, e.g., a T-cell, e.g., an engineered T-cell, in combination with a sialidase. The invention also provides compositions and methods for treating a patient with cancer with an immune cell, e.g., a T-cell, e.g., an engineered T-cell, pretreated with a sialidase.

The present invention relates to a method for the production of a sialylated glycosphingolipid, the method comprising the steps of: ─ providing a glycosphingolipid, a sialic acid donor, and an enzyme having a trans-sialidase activity, ─ mixing said glycosphingolipid with said sialic acid donor in the presence of said enzyme having trans-sialidase activity, thereby producing said sialylated glycosphingolipid, and wherein the sialic acid donor is 3´-sialyllactose.

The invention provides a sialidase enzyme activity detection kit or device comprising: (i) an indicator molecule com- prising a sialylated peptide and a capture site; (ii) a capture zone comprising capture molecules; and (iii) binding molecules capable of binding to the de-sialylated derivative of the indicator molecule. Also provided are methods of using the kits or devices, as well as specific indicator molecules and specific binding molecules.

The present invention provides a sialidase activity detection kit or device, comprising: (i) an indicator molecule, the indicator molecule comprising a sialylated peptide and a capture site; (ii) a capture zone, the capture zone comprising a capture molecule; and (iii) a binding molecule, the binding molecule being capable of binding to a desialylated derivative of the indicator molecule. Also provided are a method for using the kit or device, a specific indicator molecule, and a specific binding molecule.

The present invention relates to a method for producing a sialylated glycosphingolipid, comprising the steps of:-providing a glycosphingolipid, a sialic acid donor and an enzyme having transsialidase activity,-mixing the glycosphingolipid with the sialic acid donor in the presence of the enzyme having transsialidase activity, the sialylated glycosphingolipid is a sialylated glycosphingolipid, and wherein the sialic acid donor is 3 '-sialylated lactose.

Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.

A method of reducing or treating parainfluenza or influenza virus infection in an immunocompromised patient by administering to the respiratory tract of the patient a composition comprising a therapeutically effective amount of protein having sialidase activity.

Provided are: a biomarker for determining the stress level, which is for determining the stress level suffered by a subject by a non-invasive and simple method; a method for detecting the biomarker; a method for collecting data including the detection method; and a kit for determining the stress level. The above-mentioned purpose can be achieved by using, as a biomarker, sialidase activity of bacteria from a sample obtained from a subject. The sample is preferably excrement and / or the subject is preferably human.